BML, Inc. (TYO:4694)
Japan · Delayed Price · Currency is JPY 3,520.00
+70.00 (2.03%)
Jun 3, 2026, 3:30 PM JST
BML, Inc. Revenue
In the fiscal year ending March 31, 2026, BML, Inc. had annual revenue of 150.26B JPY with 4.94% growth. BML, Inc. had revenue of 35.79B in the quarter ending March 31, 2026, with 3.39% growth.
Revenue
150.26B
Revenue Growth
+4.94%
P/S Ratio
0.88
Revenue / Employee
32.97M
Employees
4,558
Market Cap
131.94B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 150.26B | 7.07B | 4.94% |
| Mar 31, 2025 | 143.19B | 5.23B | 3.79% |
| Mar 31, 2024 | 137.96B | -21.50B | -13.48% |
| Mar 31, 2023 | 159.46B | -26.61B | -14.30% |
| Mar 31, 2022 | 186.07B | 47.50B | 34.28% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Takeda Pharmaceutical Company | 4.51T |
| Otsuka Holdings | 2.52T |
| Chugai Pharmaceutical | 1.29T |
| HOYA Corporation | 947.75B |
| PHC Holdings | 364.40B |
| Menicon | 125.61B |
| Mochida Pharmaceutical | 116.95B |
| Kaken Pharmaceutical | 76.87B |
BML, Inc. News
- 21 days ago - BML, Inc. Quarterly report: Q4 2026 - Filings
- 21 days ago - BML, Inc. Slides: Q4 2026 - Filings
- 4 months ago - BML, Inc. Quarterly report: Q3 2026 - Filings
- 7 months ago - BML, Inc. Quarterly report: Q2 2026 - Filings
- 7 months ago - BML, Inc. Slides: Q2 2026 - Filings
- 10 months ago - BML, Inc. Quarterly report: Q1 2026 - Filings